Related Experiment Video
Updated: May 2, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Altered resting state functional connectivity in young survivors of acute lymphoblastic leukemia
Shelli R Kesler1, Meike Gugel, Mika Pritchard-Berman
1Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
Insights
Chemotherapy for pediatric acute lymphoblastic leukemia (ALL) can alter brain connectivity, impacting cognitive function. Younger children diagnosed with ALL may be more vulnerable to these neurobiological changes.
Area of Science:
- Neuroscience
- Pediatric Oncology
- Cognitive Psychology
Background:
- Chemotherapy for pediatric acute lymphoblastic leukemia (ALL) is linked to long-term cognitive deficits.
- Neurobiological mechanisms behind these cognitive impairments in young survivors are not fully understood.
Purpose of the Study:
- To investigate intrinsic functional brain connectivity in pediatric ALL survivors.
- To determine the relationship between brain connectivity and cognitive status in these patients.
Main Methods:
- Resting-state functional magnetic resonance imaging (rsfMRI) and cognitive testing were used.
- 15 pediatric ALL survivors (off-therapy ≥6 months) and 14 healthy children participated.
- Seed-based analyses compared functional brain network connectivity and explored correlations with various factors.
Main Results:
- Pediatric ALL survivors showed reduced connectivity in areas like the hippocampus and amygdala.
- Hyperconnectivity was observed in regions including the lingual gyrus and precuneus.
- Hypoconnectivity correlated with poorer cognitive function and younger age at diagnosis.
Conclusions:
- This study is the first to show disrupted intrinsic functional brain connectivity in pediatric ALL survivors post-chemotherapy.
- Altered connectivity may explain cognitive dysfunction, even with normal test performance.
- Earlier diagnosis in children may increase vulnerability to altered brain connectivity.
Background:
Chemotherapy treatment for pediatric acute lymphoblastic leukemia (ALL) has been associated with long-term cognitive impairments in some patients. However, the neurobiologic mechanisms underlying these impairments, particularly in young survivors, are not well understood. This study aimed to examine intrinsic functional brain connectivity in pediatric ALL and its relationship with cognitive status.
Procedure:
We obtained resting state functional magnetic resonance imaging (rsfMRI) and cognitive testing data from 15 ALL survivors age 8-15 years and 14 matched healthy children. The ALL group had a history of intrathecal chemotherapy treatment but were off-therapy for at least 6 months at the time of enrollment. We used seed-based analyses to compare intrinsic functional brain network connectivity between the groups. We also explored correlations between connectivity and cognitive performance, demographic, medical, and treatment variables.
Results:
We demonstrated significantly reduced connectivity between bilateral hippocampus, left inferior occipital, left lingual gyrus, bilateral calcarine sulcus, and right amygdala in the ALL group compared to controls. The ALL group also showed regions of functional hyperconnectivity including right lingual gyrus, precuneus, bilateral superior occipital lobe, and right inferior occipital lobe. Functional hypoconnectivity was associated with reduced cognitive function as well as younger age at diagnosis in the ALL group.
Conclusions:
This is the first study to demonstrate that intrinsic functional brain connectivity is disrupted in pediatric ALL following chemotherapy treatment. These results help explain cognitive dysfunction even when objective test performance is seemingly normal. Children diagnosed at a younger age may show increased vulnerability to altered functional brain connectivity.
More Related Videos
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018